Skip to main content
Clinical Trials/IRCT2016011810782N2
IRCT2016011810782N2
Completed
Phase 3

Effectiveness of a computerized cognitive remediation program on cognitive functioning of patients with schizophrenic disorders: A randomized controlled study

Tehran University of Medical Sciences0 sites62 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Condition 1: Schizoaffective Disorder. Condition 2: Schizophrenia.
Sponsor
Tehran University of Medical Sciences
Enrollment
62
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with DSM\-IV schizophrenia or schizoaffective disorder, aged 18 to 55 years and with education not less than 3rd grade in guidance school. Patients will be clinically stable and not acutely psychotic (Clinical Global Impression scale score less than 4, and Positive and Negative Syndrome Scale score less than 50\). The dosage and the type of antipsychotic medications patients will receive at least during the three weeks prior to the study will be unchanged. At least 12 hours before the intervention, patients will receive their last dose of a benzodiazepine (if any) but no antihistamine medication will be administered.
  • Exclusion criteria:
  • Receiving electroconvulsive therapy (ECT) within six weeks prior to the study, mental retardation, uncorrected visual impairment, concurrent consumption of substances with the exception of nicotine and caffeine, a history of head trauma followed by loss of consciousness, suffering from a major neurological disorder (including epilepsy, Parkinson’s disease, dementia, multiple sclerosis, or any motor disability), severe worsening of illness during study requiring a change in medical treatments.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials